keyword
MENU ▼
Read by QxMD icon Read
search

Second line docetaxel with carboplatin

keyword
https://www.readbyqxmd.com/read/27817234/-effective-systemic-palliative-chemotherapy-for-intracranial-metastases-of-breast-cancer
#1
István Sipőcz, Tamás Pintér, Zoltán Skaliczky, Tamás Kullmann
The authors present the history of two patients. The first patient, a 69-year-old woman was diagnosed with locally invasive triple negative breast cancer with pulmonary and cerebral metastases. Complete radiological remission of the clinically asymptomatic cerebral metastases was detected under systemic chemotherapy with carboplatin-docetaxel (75 mg/m(2)). Later, the patient received whole brain radiotherapy and a second line of chemotherapy. The overall survival was 20 months from the diagnosis of cerebral metastases with conservation of partial autonomy...
November 2016: Orvosi Hetilap
https://www.readbyqxmd.com/read/27266233/quality-of-life-achieved-by-carboplatin-plus-etoposide-as-third-line-chemotherapy-compared-with-best-supportive-care-in-non-small-cell-lung-cancer-stage-iiib-iv
#2
COMPARATIVE STUDY
Jedzada Maneechawakajorn, Sitthichok Hathaisanguan
BACKGROUND: Advanced stage (IIIB/IV) non-small cell lung cancers (NSCLC) are mostly treated with paclitaxel or gemcitabine combination chemotherapy as first-line treatment and docetaxel as second-line therapy under the national reimbursement program, but there is no treatment specified for use after disease progression. New third-line chemotherapy drugs including new targeted therapies are expensive and bring about only slightly prolonged progression-free survival and minimally better response in healthy patients...
February 2016: Journal of the Medical Association of Thailand, Chotmaihet Thangphaet
https://www.readbyqxmd.com/read/26324367/systemic-therapy-for-stage-iv-non-small-cell-lung-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update
#3
Gregory A Masters, Sarah Temin, Christopher G Azzoli, Giuseppe Giaccone, Sherman Baker, Julie R Brahmer, Peter M Ellis, Ajeet Gajra, Nancy Rackear, Joan H Schiller, Thomas J Smith, John R Strawn, David Trent, David H Johnson
PURPOSE: To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non-small-cell lung cancer (NSCLC). METHODS: An Update Committee of the American Society of Clinical Oncology NSCLC Expert Panel based recommendations on a systematic review of randomized controlled trials from January 2007 to February 2014. RESULTS: This guideline update reflects changes in evidence since the previous guideline...
October 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26124377/combination-chemotherapy-with-itraconazole-for-treating-metastatic-pancreatic-cancer-in-the-second-line-or-additional-setting
#4
Hiroshi Tsubamoto, Takashi Sonoda, Shinichi Ikuta, Satoshi Tani, Kayo Inoue, Naoki Yamanaka
BACKGROUND: We evaluated chemotherapy with itraconazole (a common anti-fungal agent that is a potent inhibitor of the Hedgehog pathway, P-glycoprotein, and angiogenesis) for treating progressive pancreatic cancer. PATIENTS AND METHODS: We retrospectively reviewed the medical charts of patients with histologically-diagnosed pancreatic cancer who had received first- or second-line chemotherapy and subsequent chemotherapy with itraconazole. RESULTS: A total of 38 patients received docetaxel (35 mg/m(2)), gemcitabine (1,000 mg/m(2)), and carboplatin (area under the curve, 4 mg/min/ml) on day 1 and oral itraconazole solution (400 mg) on days -2 to 2, repeated every 2 weeks...
July 2015: Anticancer Research
https://www.readbyqxmd.com/read/26092322/what-is-an-appropriate-second-line-regimen-for-recurrent-endometrial-cancer-ancillary-analysis-of-the-sgsg012-gotic004-intergroup-study
#5
MULTICENTER STUDY
Shoji Nagao, Shin Nishio, Satoshi Okada, Takeo Otsuki, Kiyoshi Fujiwara, Hiroshi Tanabe, Masashi Takano, Yoko Hasumi, Yuji Takei, Tetsuya Hasegawa, Takashi Matsumoto, Keiichi Fujiwara, Munetaka Takekuma, Kazuto Nakamura, Muneaki Shimada, Mitsuaki Suzuki, Junzo Kigawa
PURPOSE: We previously reported that the concept of "platinum sensitivity" could be applied to recurrent endometrial cancer. We conducted an ancillary analysis to determine an appropriate second-line regimen for patients who received a platinum agent as first-line chemotherapy. METHODS: We extracted and reanalyzed data of patients treated with doxorubicin and cisplatin (AP), paclitaxel and carboplatin (TC), or docetaxel and carboplatin (DC) as first- and second-line chemotherapies from the SGSG012/GOTIC004/Intergroup study...
August 2015: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/26055179/drug-resistant-urothelial-cancer-cell-lines-display-diverse-sensitivity-profiles-to-potential-second-line-therapeutics
#6
Stefan Vallo, Martin Michaelis, Florian Rothweiler, Georg Bartsch, Kilian M Gust, Dominik M Limbart, Franz Rödel, Felix Wezel, Axel Haferkamp, Jindrich Cinatl
Combination chemotherapy with gemcitabine and cisplatin in patients with metastatic urothelial cancer of the bladder frequently results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance could help to identify candidate treatments for an efficient second-line therapy. Six cisplatin- and six gemcitabine-resistant cell lines were established. Cell viability assays were performed to evaluate the sensitivity to 16 different chemotherapeutic substances. The activity of the drug transporter ATP-binding cassette transporter, subfamily B, member 1 (ABCB1, a critical mediator of multidrug resistance in cancer) was evaluated using fluorescent ABCB1 substrates...
June 2015: Translational Oncology
https://www.readbyqxmd.com/read/25947099/the-role-of-anti-angiogenesis-in-non-small-cell-lung-cancer-an-update
#7
REVIEW
Liza C Villaruz, Mark A Socinski
Recognition of the vascular endothelial growth factor (VEGF) pathway as a key mediator of angiogenesis has led to the clinical study of several VEGF and VEGF receptor (VEGFR) targeted therapies in non-small-cell lung cancer (NSCLC). These targeted therapies include neutralizing antibodies to VEGF (bevacizumab and aflibercept) and VEGFR-2 (ramucirumab) and tyrosine kinase inhibitors (TKIs) with selectivity for the VEGFRs. Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting...
June 2015: Current Oncology Reports
https://www.readbyqxmd.com/read/25687848/results-of-a-phase-ii-study-to-evaluate-the-efficacy-of-docetaxel-and-carboplatin-in-metastatic-malignant-melanoma-patients-who-failed-first-line-therapy-containing-dacarbazine
#8
Choong-kun Lee, Minkyu Jung, Hye Jin Choi, Hye Ryun Kim, Hyo Song Kim, Mi Ryung Roh, Joong Bae Ahn, Hyun Cheol Chung, Su Jin Heo, Sun Young Rha, Sang Joon Shin
PURPOSE: There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. MATERIALS AND METHODS: We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel combined with carboplatin for malignant melanoma patients who failed previous treatment with dacarbazine. Intravenous docetaxel (35 mg/m(2) on days 1 and 8 of each cycle) and carboplatin (area under the curve 3 on days 1 and 8 of each cycle) was administered every 21 days...
October 2015: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/25494701/a-multicenter-non-randomized-phase-ii-study-of-docetaxel-and-carboplatin-administered-every-3-weeks-as-second-line-chemotherapy-in-patients-with-first-relapse-of-platinum-sensitive-epithelial-ovarian-peritoneal-or-fallopian-tube-cancer
#9
MULTICENTER STUDY
Yun Wang, Jørn Herrstedt, Hanne Havsteen, Rene DePoint Christensen, Mansoor Raza Mirza, Bente Lund, Johanna Maenpaa, Gunnar Kristensen
BACKGROUND: In patients with ovarian cancer relapsing at least 6 months after end of primary treatment, the addition of paclitaxel to platinum treatment has been shown to improve survival but at the cost of significant neuropathy. In the first line setting, the carboplatin-docetaxel combination was as effective as the combination of carboplatin and paclitaxel but with less neurotoxicity. This study was initiated to evaluate the feasibility of carboplatin with docetaxel as second line treatment in patients with ovarian, peritoneal or fallopian tube cancer...
December 11, 2014: BMC Cancer
https://www.readbyqxmd.com/read/25432369/-clinical-study-on-chemotherapy-of-lobaplatin-combined-with-docetaxel-in-patients-with-relapsed-ovarian-cancer
#10
Xinchun Li, Yinghua Li
OBJECTIVE: To evaluate the efficacy and safety of lobaplatin combined with docetaxel in the treatment of the recurrent ovarian carcinoma. METHODS: We collected 31 patients who diagnosed as recurrent ovarian carcinoma according to the histopathology or cytology from Tumor Hospital of Hunan Province from January 2011 to January 2013. The patients received cisplatin-based chemotherapy or carboplatin-based chemotherapy before the combined chemotherapy of docetaxel and lobaplatin...
November 2014: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/25392156/the-role-of-chemotherapy-for-metastatic-relapsed-and-refractory-osteosarcoma
#11
REVIEW
Xin Xiao, Wei Wang, Zhen Wang
UNLABELLED: Despite a large number of publications on outcomes of second-line chemotherapy for osteosarcoma, there is little consensus on efficacy of the therapy. OBJECTIVE: Our objective was to systematically categorize published evidence for chemotherapy for metastatic, relapsed and refractory osteosarcoma in order to provide an updated and comprehensive analysis of the clinical outcomes. METHODS: We performed a search of PubMed and EMBASE to identify published articles reporting on validated clinical outcomes measures (the rate of complete response [CR] and partial response [PR], the rate of stable disease [SD] and progressive disease [PD] and the 5-year overall survival) after chemotherapy in patients with metastatic, relapsed and refractory osteosarcoma...
December 2014: Paediatric Drugs
https://www.readbyqxmd.com/read/25248391/simulation-and-comparison-of-progression-free-survival-among-patients-with-non-squamous-non-small-cell-lung-cancer-receiving-sequential-therapy
#12
COMPARATIVE STUDY
Stefan Walzer, Christos Chouaid, Johanna Lister, Dmitry Gultyaev, Alain Vergnenegre, Filippo de Marinis, Jie Meng, Javier de Castro Carpeno, Ralph Crott, Martin Kleman, Charles Ngoh
OBJECTIVES: In recent years, the treatment landscape in advanced non-squamous non-small-cell lung cancer (nsNSCLC) has changed. New therapies (e.g., bevacizumab indicated in first line) have become available and other therapies (e.g., pemetrexed in first line and second line) moved into earlier lines in the treatment paradigm. While there has been an expansion of the available treatment options, it is still a key research question which therapy sequence results in the best survival outcomes for patients with nsNSCLC...
January 2015: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/24917010/-a-case-of-primary-unknown-cancer-difficult-to-distinguish-from-lung-cancer
#13
Yoko Tanaka, Kentaro Tago, Tomoko Narabayashi, Yoshiaki Sasaki, Eriko Iwahashi, Chihiro Hibino, Teruo Iwasaki, Takahiro Watanabe, Tsutomu Kasugai, Joji Kohama, Kiyoshi Ohno
A 26-year-old man was admitted to our hospital with dyspnea, fever, and weight loss. A chest X-ray showed multiple tumor shadows, and a computed tomography (CT) scan showed swelling of the mediastinal and hilar lymph nodes, a mass in the retroperitoneum, and an embolus in the inferior vena cava. A biopsy from the left cervical lymph node revealeda poorly differentiated adenocarcinoma. Metastatic lung cancer was suspected, but in spite of the examinations, its primary site was unknown. Serum alfa-fetoprotein(AFP)was slightly elevated, but an AFP stain of the tumor was negative...
May 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/24865474/carboplatin-based-combination-chemotherapy-for-elderly-patients-with-advanced-bladder-cancer
#14
Takahiro Yoneyama, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama
BACKGROUND: We evaluated retrospectively the feasibility and effectiveness of carboplatin-based combination chemotherapy in elderly patients with advanced bladder cancer. METHODS: Forty-seven patients with advanced bladder cancer (33 men and 14 women) and treated at our hospital between August 2004 and December 2011 were enrolled. The average age was 77.1 years (range 70-86 years), the average creatinine clearance was 37.0 ml/min (range 14.5-113.0 ml/min), and the average follow-up period was 17...
April 2015: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/24088763/long-term-remission-achieved-via-combined-chemotherapy-and-radiotherapy-in-a-non-resectable-granulocyte-colony-stimulating-factor-producing-pleomorphic-carcinoma-of-the-lung
#15
Masaki Yamamoto, Saki Manabe, Yusuke Moriyama, Hiroshi Ishii, Shintetsu Tanaka, Ryohei Takahashi, Koji Tomaru, Nobuaki Kobayashi, Makoto Kudo, Masahiro Sasaki, Yoshiaki Inayama, Takeshi Kaneko, Yoshiaki Ishigatsubo
The prognosis is poor for patients with advanced pleomorphic carcinoma of the lung due to the generally limited response to chemotherapy and/or radiotherapy. It has been suggested the production of granulocyte colony-stimulating factor (G-CSF) by cancer cells may aggravate the disease progression. We herein report a case of a 73-year-old Japanese man with advanced G-CSF-producing pleomorphic carcinoma of the lung. First-line chemotherapy with carboplatin and paclitaxel had been suspended. Subsequent radiotherapy achieved a moderate volume reduction and an amelioration of the excessive G-CSF-related complications...
2013: Internal Medicine
https://www.readbyqxmd.com/read/23996521/targeted-therapies-for-locally-advanced-or-metastatic-squamous-cell-carcinoma-of-the-lung
#16
Thomas E Stinchcombe
Most patients with squamous cell carcinoma (SCC) present with advanced or metastatic disease at the time of diagnosis. Given the low prevalence of oncogenic driver mutations in SCC, I do not routinely perform molecular testing. The times that I perform molecular testing in SCC are for patients with SCC and a light or never smoking history, adenosquamous histology, or when the histological diagnosis is not definitive. For patients with a good performance status and adequate organ function, a platinum doublet is the standard therapy, and I generally use carboplatin and gemcitabine or carboplatin and paclitaxel...
December 2013: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/23914849/surgical-and-chemotherapeutic-experience-regarding-a-urachal-carcinoma-with-repeated-relapse-case-report-and-literature-review
#17
REVIEW
Liang Zong, Ping Chen
BACKGROUND: Urachal carcinoma is a rare tumor that is usually associated with a poor prognosis, especially the pathological type, urachal mucinous adenocarcinoma. Surgery remains the primary treatment in prolonging the overall survival time of patients. CASE PRESENTATION: We report on a 41-year-old woman with urachal mucinous adenocarcinoma who underwent three surgeries and several courses of chemotherapy over a 42-month period. The first surgery, involving en-bloc excision of the urachal mass, partial urinary bladder, urachal ligament, and umbilicus was performed in May 2007...
2013: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/23880598/a-phase-ii-study-of-combination-chemotherapy-using-docetaxel-and-irinotecan-for-tc-refractory-or-tc-resistant-ovarian-carcinomas-gogo-ov2-study-and-for-primary-clear-or-mucinous-ovarian-carcinomas-gogo-ov3-study
#18
Yutaka Ueda, Takashi Miyatake, Masaaki Nagamatsu, Masato Yamasaki, Yukihiro Nishio, Kiyoshi Yoshino, Masami Fujita, Tateki Tsutsui, Takayuki Enomoto, Tadashi Kimura
OBJECTIVE: To analyze the efficacy and safety of combination chemotherapy of docetaxel and irinotecan for paclitaxel and carboplatin (TC) -refractory or -resistant ovarian carcinomas and for first treatment of primary clear cell and mucinous ovarian carcinomas. STUDY DESIGN: Between 2002 and 2009, we conducted a prospective Phase II study of the efficacy and safety of combination chemotherapy using docetaxel and irinotecan in 62 patients with TC-refractory or -resistant ovarian carcinoma cases (GOGO-OV2) and 15 patients with primary clear cell and mucinous ovarian carcinoma cases (GOGO-OV3)...
September 2013: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/23863745/-a-case-of-recurrent-endometrial-carcinoma-with-pleural-effusion-maintained-long-sd-by-pegylated-liposomal-doxorubicin-pld-chemotherapy
#19
Yuichiro Miyamoto, Kimihiro Takechi
We experienced a case of long SD through the use of pegylated liposomal doxorubicin(PLD)chemotherapy for recurrent endometrial carcinoma with pleural effusion. The patient was an 82-year-old woman with recurrent endometrial carcinoma. At 76 years of age, she underwent extended abdominal hysterectomy, bilateral salpingo-oophorectomy and pelvic·paraaortic lymphadenectomy for the diagnosis of endometrial carcinoma(serous adenocarcinoma)Stage IIIc. She also received adjuvant chemotherapy with paclitaxel(175mg/m2)and carboplatin(AUC 6), and radiotherapy...
July 2013: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/23714545/current-state-of-the-art-therapy-for-advanced-squamous-cell-lung-cancer
#20
REVIEW
Giorgio V Scagliotti, Silvia Novello, Simonetta Rapetti, Mauro Papotti
Squamous cell carcinoma (SCC) represents the second most common histologic subtype of lung cancer (preceded only by adenocarcinoma). SSC of the lung is prevalently diagnosed in smokers and has been described as a preferentially centrally located tumor in which the main airways are commonly involved. Clinically, it presents with predominant locoregional signs and symptoms, but in recent years an increasing frequency of peripheral SCC of the lung has been reported. Pathologic diagnosis can be easily made through light microscopy and immunohistochemistry...
2013: American Society of Clinical Oncology Educational Book
keyword
keyword
79034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"